- Home
- RNAC vs GNLX Comparison
RNAC vs GNLX Comparison
Compare RNAC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | GNLX |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 202.4M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RNAC | GNLX |
|---|---|---|
| Price | $6.88 | $4.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $38.40 | $19.75 |
| AVG Volume (30 Days) | 138.3K | ★ 231.7K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,091,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $1.99 |
| 52 Week High | $26.50 | $8.54 |
Technical Indicators
Market Signals| Indicator | RNAC | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 37.91 |
| Support Level | $6.53 | $4.41 |
| Resistance Level | $7.73 | $5.89 |
| Average True Range (ATR) | 0.43 | 0.49 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 29.23 | 14.19 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.